CRISPR Therapeutics AG
CRSP
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programsā¦ read more
Healthcare
Biotechnology
9 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$55.12
Price-2.63%
-$1.49
1Y
Price
Market Cap
$5.013b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-22719.4%
EBITDA Margin-23379.9%
Net Profit Margin-12779.9%
Free Cash Flow MarginRevenue
$37.359m
+6.7%
1y CAGR+28318.4%
3y CAGR+21213.8%
5y CAGREarnings
-$467.798m
-27.7%
1y CAGR-29.9%
3y CAGR-90.5%
5y CAGREPS
-$5.43
-25.1%
1y CAGR-24.0%
3y CAGR-87.5%
5y CAGRBook Value
$1.711b
$2.030b
Assets$318.586m
Liabilities$215.452m
DebtDebt to Assets
10.6%
-0.4x
Debt to EBITDAFree Cash Flow
-$325.567m
-125.0%
1y CAGR-9.7%
3y CAGR-61.4%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company